-
A decade of integrated drug discovery at Symeres
Symeres celebrates a decade of integrated drug discovery. Our team has been working hard to provide our clients with the best possible solutions for their needs.
Latest patents
-
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same (Organix)
Number: US 2023/0056273 A1
-
Triazole derivatives and their use as tankyrase inhibitors
Number: WO 2022/008896 A1
-
Conjugate of saponin, oligonucleotide and galnac
Number: WO 2022/055351 A1
Latest publications
-
Contemporary Chiral Resolutions
Article: Chim. Oggi., 2023, 41 (2)
-
Comparative biochemical kinase activity analysis identifies rivoceranibas a highly selective VEGFR2 inhibitor (Oncolines)
Article: Cancer Chemother Pharmacol., 2023 (6), 491-499
-
DT-0111: a novel P2X3 receptor antagonist (Organix)
Article: Purinergic Signalling, 2023
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
